Platelet P2Y receptor (P2Y (when referring to the family), P2Y1 and P2Y12 (when specific))

Platelet P2Y receptors are a subset of G protein-coupled purinergic receptors (primarily P2Y1 and P2Y12) that mediate platelet activation and aggregation in response to ADP. P2Y1 initiates platelet activation and shape change, while P2Y12 sustains aggregation and thrombus formation. Both receptors are therapeutic targets for antiplatelet agents that aim to prevent arterial thrombosis and cardiovascular events. Antagonists of P2Y12, such as clopidogrel, prasugrel, ticagrelor, and cangrelor, are widely used clinically for heart attack and stroke prevention, but their administration must be balanced against bleeding risks. Genetic and pharmacological variability may affect individual responses to P2Y12-targeted drugs.

Other names

Platelet ADP receptorPlatelet purinergic receptorP2Y1 receptorP2Y12 receptorP2Y receptor family (only in the context of platelets)

Antagonism (blockade) of P2Y12 receptor prevents ADP-mediated platelet aggregation Antagonism of P2Y1 receptor inhibits early platelet activation Covalent inhibition (thienopyridines like clopidogrel and prasugrel) Reversible antagonism (ticagrelor, cangrelor, elinogrel)